Companies › Servier Affaires Médicales
1 active drug program in 31 registered trials: 15 Phase 2, 10 Phase 1, 6 Phase 3; Hematology, Oncology; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ivosidenib Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1 | Phase 3 | Acute Myeloid Leukemia (AML); Cholangiocarcinoma; Newly Diagnosed Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia … | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02632708 | Ivosidenib | Phase 1 | Newly Diagnosed Acute Myeloid Leukemia (AML) | Hematology | Dec 2018 |
| NCT03173248 | Ivosidenib | Phase 3 | Newly Diagnosed Acute Myeloid Leukemia (AML) | Oncology | Mar 2021 |
| NCT07282262 | Ivosidenib | Phase 2 | Biliary Tract Cancer | Oncology | Oct 2026 |
| NCT07007949 | Ivosidenib | Phase 2 | Acute Myeloid Leukemia | Oncology | Dec 2026 |
| NCT05010772 | Ivosidenib | Phase 1 | Acute Myeloid Leukemia | Oncology | Dec 2026 |
| NCT02074839 | Ivosidenib | Phase 1 | Relapsed or Refractory Acute Myeloid Leukemia (AML) | Oncology | Dec 2026 |
| NCT05209074 | Ivosidenib | Phase 1 | Pancreatic Ductal Adenocarcinoma | Oncology | Dec 2026 |
| NCT03155620 | Ivosidenib | Phase 2 | Advanced Malignant Solid Neoplasm | Oncology | Jan 2027 |
| NCT04278781 | Ivosidenib | Phase 2 | Chondrosarcoma | Oncology | Mar 2027 |
| NCT03503409 | Ivosidenib | Phase 2 | Myelodysplastic Syndromes | Oncology | Apr 2027 |
| NCT03839771 | Ivosidenib | Phase 3 | Acute Myeloid Leukemia | Oncology | Apr 2027 |
| NCT05756777 | Ivosidenib | Phase 1 | Acute Myeloid Leukemia (AML) | Oncology | Apr 2027 |
| NCT04195555 | Ivosidenib | Phase 2 | Recurrent Ependymoma | Oncology | May 2027 |
| NCT07607418 | Ivosidenib | Phase 2 | AML (Acute Myeloid Leukemia) | Hematology | May 2027 |
| NCT05615818 | Ivosidenib | Phase 3 | Biliary Tract Neoplasms | Oncology | Jun 2027 |
| NCT06501625 | Ivosidenib | Phase 1 | Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation | Oncology | Sep 2027 |
| NCT05401097 | Ivosidenib | Phase 2 | Acute Myeloid Leukemia | Oncology | Sep 2027 |
| NCT03471260 | Ivosidenib | Phase 1 | Acute Myeloid Leukemia | Oncology | Sep 2027 |
| NCT05907057 | Ivosidenib | Phase 3 | Acute Myeloid Leukemia (AML) | Oncology | Oct 2027 |
| NCT06465953 | Ivosidenib | Phase 3 | Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) | Hematology | Nov 2027 |
| NCT04774393 | Ivosidenib | Phase 1 | Acute Myeloid Leukemia | Oncology | Nov 2027 |
| NCT05876754 | Ivosidenib | Phase 3 | Cholangiocarcinoma | Oncology | Dec 2027 |
| NCT06707493 | Ivosidenib | Phase 2 | IDH1 Mutation | Oncology | Jan 2028 |
| NCT07392242 | Ivosidenib | Phase 2 | Acute Myeloid Leukemia | Oncology | Jan 2028 |
| NCT04493164 | Ivosidenib | Phase 2 | Acute Myeloid Leukemia With Gene Mutations | Oncology | Jun 2028 |
| NCT06611839 | Ivosidenib | Phase 1 | AML | Oncology | Oct 2028 |
| NCT07507760 | Ivosidenib | Phase 2 | Acute Myeloid Leukemia With Gene Mutations | Oncology | Apr 2029 |
| NCT06291987 | Ivosidenib | Phase 1 | Myeloproliferative Neoplasms | Oncology | May 2029 |
| NCT06717958 | Ivosidenib | Phase 2 | AML | Oncology | Oct 2029 |
| NCT05030441 | Ivosidenib | Phase 2 | Clonal Cytopenia of Undetermined Significance | Oncology | Jan 2030 |
| NCT07260175 | Ivosidenib | Phase 2 | Cholangiocarcinoma | Oncology | Dec 2030 |
Servier Eli Lilly Nuvation Bio Bristol-Myers Squibb Kissei Pharmaceutical Hutchmed Rigel Pharmaceuticals Servier Bio-Innovation Novartis Daiichi Sankyo
Servier Institut de Recherches Internationales Servier (I.R.I.S.) Geron Syntrix Biosystems Electra Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.